Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking
A legfontosabb adatok
- Ki végzi
- Argon Medical Devices
- Hol
- Edgewood, Fort Lauderdale, Indianapolis és Plano (Egyesült Államok)Mind a 4 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 185 fő, tervezett
- Kezdés
- 2026. febr. 4.
- Várható befejezés
- 2029. jún.
- A vizsgálat típusa
- Megfigyeléses
- A vizsgált kezelések
- Aspiration thrombectomy system
- A regiszteradat frissítve
- 2026. október 20.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with a recent blood clot in a deep vein of the leg or pelvis. They will be treated first with the Cleaner Vac® Thrombectomy System, a device that sucks out the clot.
- Életkor
- 18 years or older.
- Nem
- All sexes.
- A betegség stádiuma
- Deep vein thrombosis (DVT) in one or both legs. It must involve the femoral-popliteal, common femoral or iliac vein, or the inferior vena cava (IVC). Symptoms started within 6 weeks of enrollment. Imaging confirmed the clot within 14 days of the procedure.
- Korábbi kezelés
- The Cleaner Vac® device must be the first treatment for the clot. People cannot join if clot-dissolving drugs (thrombolytics) were used on the same vein in the previous 14 days.
A részvétel fő kizáró okai
- Cannot take blood thinners, or cannot have iodine contrast dye even with medicine given beforehand.
- Pregnancy.
- Severe kidney problems (GFR < 30 ml/min) without dialysis. People already on dialysis can join.
- Intermediate-high or high-risk clot in the lung (pulmonary embolism), or a known patent foramen ovale (PFO), a small opening between the heart's upper chambers.
- Life expectancy less than 1 year due to advanced cancer, or long-term inability to walk.
A regiszter feltételei, szó szerint
Mind a 22 feltétel megnézéseKevesebb
Ki vehet részt
- Participants must meet all the following criteria to be eligible for the study:
- At least 18 years of age at the time of consent
- Undergo frontline (primary) treatment with Cleaner Vac® Thrombectomy System in the peripheral venous vasculature and have at least one component introduced into the body
- Written informed consent obtained through the IRB-approved ICF; For the DVT cohort, participants must meet all criteria above and below to be eligible for the study:
- Present with unilateral or bilateral lower extremity DVT involving at least one of the following veins:; Femoral-popliteal vein; Common femoral vein; Iliac vein; Inferior Vena Cava (IVC)
- DVT diagnosis confirmed by imaging within 14 days of the index procedure
- Symptomatic DVT with onset within 6 weeks of enrollment
Ki nem vehet részt
- Treatment of target venous segment with thrombolytics within previous 14 days of the index procedure
- Current enrollment in another investigational device or drug study that may confound the results of this study. Studies requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational studies
- Life expectancy less than 1 year due to advanced malignancy, as determined by the investigator at the time of enrollment
- Known coagulation disorders both acquired (Heparin Induced Thrombocytopenia, etc.) or genetic (e.g., Factor V Leiden, etc.), thrombophilia, or hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period
- Known history of a Patent Foramen Ovale (PFO)
- Patients with intermediate-high risk or high-risk pulmonary embolism (PE) defined as follows:; High-risk PE: Presence of hemodynamic instability, including cardiac arrest, obstructive shock (systolic blood pressure <90 mmHg or need for vasopressors with signs of end-organ hypoperfusion), or persistent hypotension (systolic BP <90 mmHg or a drop ≥40 mmHg for >15 minutes not due to other causes); Intermediate-high-risk PE: Hemodynamically stable patients with both right ventricular (RV) dysfunction (on echocardiography or CT) and elevated cardiac biomarkers (e.g., troponin)
- Hemoglobin < 8.0 g/dL, INR > 2.0 before warfarin was started, or platelets < 50,000/µl which cannot be corrected prior to enrollment
- Severe renal impairment (estimated GFR < 30 ml/min) in patients who are not yet on dialysis. Patients with GFR <30 ml/min who are already on dialysis can be enrolled
- Subjects will be excluded from the study if any of the following criteria are met:
- Contraindication to systemic or therapeutic doses of anticoagulants
- Contraindication to iodinated contrast that cannot be adequately premedicated
- Patients that are pregnant
- Known congenital anatomic anomalies of the inferior vena cava (IVC) or iliac veins
- Complete infrarenal IVC occlusion
- Chronic non-ambulatory status
Helyszínek itt: Egyesült Államok
- St. Elizabeth Healthcare - EdgewoodEdgewood, Egyesült ÁllamokContact: Alisha HartmannRésztvevőt keres
- Janna, LLCFort Lauderdale, Egyesült ÁllamokContact: Vicky RodriguezRésztvevőt keres
- Indiana University HealthIndianapolis, Egyesült ÁllamokContact: Siji MathachanRésztvevőt keres
- Baylor Scott & White The Heart Hospital - PlanoPlano, Egyesült ÁllamokContact: Erika V Ortiz, BARésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The primary objective of this clinical investigation is to evaluate the safety and effectiveness of the Cleaner Vac® Thrombectomy System for the treatment of thrombus in patients with lower extremity proximal deep vein thrombosis (DVT). This prospective, multi-center, open-label study will assess clinical outcomes, device performance, and procedural success in a single DVT study cohort.
A vizsgálat csoportja
- DVT Subgroup
This is a defined cohort focused on patients with lower extremity proximal deep vein thrombosis (DVT) who will undergo treatment with Cleaner Vac® Thrombectomy System. Participants will complete required follow-up at discharge and at 1, 6, 12, and 24 months.
Kezelés: Aspiration thrombectomy system
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Prospective, Multi-Center, Open-Label Clinical Investigation of the Cleaner Vac® Thrombectomy System for Treatment of Lower Extremity Proximal Deep Vein Thrombosis (DVT)
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- A regiszteradat frissítve
- 2026. október 20.